Shoppers Who Buy Via Email Spend 138% More Than Those Who Don't. Here Are 9 Email Hacks to Capture Their Sales
Jennison Associates LLC acquired a new position in shares of Myriad Genetics, Inc. ( NASDAQ:MYGN – Free Report ) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 24,162 shares of the company’s stock, valued at approximately $662,000. A number of other hedge funds and other institutional investors also recently bought and sold shares of MYGN. Hexagon Capital Partners LLC increased its position in shares of Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock worth $28,000 after purchasing an additional 491 shares in the last quarter. Innealta Capital LLC purchased a new position in Myriad Genetics during the 2nd quarter worth $36,000. GAMMA Investing LLC increased its position in Myriad Genetics by 34.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after buying an additional 412 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Myriad Genetics in the second quarter valued at about $60,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Myriad Genetics in the second quarter worth about $82,000. Hedge funds and other institutional investors own 99.02% of the company’s stock. Insider Buying and Selling at Myriad Genetics In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares in the company, valued at approximately $1,188,797.35. This represents a 51.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, CEO Paul J. Diaz sold 15,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now owns 962,378 shares in the company, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last ninety days, insiders sold 71,012 shares of company stock valued at $1,900,485. 2.10% of the stock is owned by company insiders. Analyst Ratings Changes Read Our Latest Stock Analysis on MYGN Myriad Genetics Stock Up 2.4 % Shares of MYGN opened at $15.49 on Friday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -11.92 and a beta of 1.93. Myriad Genetics, Inc. has a 52 week low of $14.72 and a 52 week high of $29.30. The stock’s 50-day moving average price is $22.26 and its 200-day moving average price is $24.48. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics Profile ( Free Report ) Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. Featured Articles Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter .Taylor Swift live updates: Eras takes Vancouver for tour’s final 3 nights
NoneTikTok is inching closer to a potential ban in the US. So what's next?None
A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say. Offering patients an injection is more effective than the current care of steroid tablets and cuts the need for further treatment by 30%, according to a study. Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used as a repeat treatment for severe asthma at a low dose, but a new clinical trial has found that a higher single dose can be very effective if injected at the time of a flare-up. The findings, published in the Lancet Respiratory Medicine, included 158 people who needed medical attention in A&E for their asthma or COPD attack (COPD is a group of lung conditions that cause breathing difficulties). Patients were given a quick blood test to see what type of attack they were having, with those suffering an “eosinophilic exacerbation” involving eosinophils (a type of white blood cell) being suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according to the scientists. The clinical trial, led by King’s College London and carried out at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, saw patients randomly split into three groups. One group received the benralizumab injection and dummy tablets, another received standard care (prednisolone steroids 30mg daily for five days) and a dummy injection, and the third group received both the benralizumab injection and steroids. After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better in people on benralizumab. And after 90 days, there were four times fewer people in the benralizumab group who failed treatment compared with those receiving steroids. Treatment with the benralizumab injection also took longer to fail, meaning fewer visits to a GP or hospital for patients, researchers said. Furthermore, people also reported a better quality of life on the new regime. Scientists at King’s said steroids can have severe side-effects such as increasing the risk of diabetes and osteoporosis, meaning switching to benralizumab could provide huge benefits. Lead investigator Professor Mona Bafadhel, from King’s, said: “This could be a game-changer for people with asthma and COPD. “Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined. “Benralizumab is a safe and effective drug already used to manage severe asthma. “We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.” Researchers said benralizumab could also potentially be administered safely at home or in a GP practice, as well as in A&E. First author Dr Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia, said: “Our study shows massive promise for asthma and COPD treatment. “COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. “We need to provide these patients with life-saving options before their time runs out.” Dr Samantha Walker, director of research and innovation at Asthma and Lung UK, welcomed the findings but said: “It’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is.” AstraZeneca provided the drug for the study and funded the research, but had no input into trial design, delivery, analysis or interpretation.No. 21 Creighton's Steven Ashworth doubtful for Players Era Festival opener against Aztecs
Target Co. ( NYSE:TGT – Get Free Report ) has earned an average rating of “Moderate Buy” from the thirty-two brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $162.13. A number of research firms recently issued reports on TGT. Daiwa America upgraded shares of Target to a “strong-buy” rating in a report on Monday, August 26th. Melius Research began coverage on shares of Target in a research note on Monday, September 23rd. They set a “buy” rating and a $180.00 price target for the company. Stifel Nicolaus dropped their price objective on Target from $165.00 to $137.00 and set a “hold” rating on the stock in a research note on Thursday. Hsbc Global Res downgraded Target from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Jefferies Financial Group upped their price target on Target from $190.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Get Our Latest Stock Analysis on Target Insider Buying and Selling at Target Institutional Trading of Target Several hedge funds and other institutional investors have recently made changes to their positions in TGT. Cynosure Group LLC raised its holdings in Target by 4.3% in the third quarter. Cynosure Group LLC now owns 1,590 shares of the retailer’s stock worth $248,000 after buying an additional 65 shares during the last quarter. Financial Advocates Investment Management increased its position in shares of Target by 1.2% during the third quarter. Financial Advocates Investment Management now owns 5,736 shares of the retailer’s stock valued at $894,000 after acquiring an additional 67 shares in the last quarter. Hancock Whitney Corp raised its holdings in Target by 3.3% in the 3rd quarter. Hancock Whitney Corp now owns 2,156 shares of the retailer’s stock worth $336,000 after acquiring an additional 68 shares during the last quarter. Beacon Capital Management LLC lifted its position in Target by 20.8% in the 2nd quarter. Beacon Capital Management LLC now owns 400 shares of the retailer’s stock valued at $59,000 after acquiring an additional 69 shares in the last quarter. Finally, Integral Investment Advisors Inc. lifted its position in Target by 5.3% in the 2nd quarter. Integral Investment Advisors Inc. now owns 1,382 shares of the retailer’s stock valued at $203,000 after acquiring an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 79.73% of the company’s stock. Target Stock Up 2.8 % TGT stock opened at $125.01 on Friday. The stock’s 50 day moving average is $151.27 and its 200-day moving average is $149.61. Target has a twelve month low of $120.21 and a twelve month high of $181.86. The firm has a market capitalization of $57.59 billion, a PE ratio of 13.26, a P/E/G ratio of 1.57 and a beta of 1.24. The company has a quick ratio of 0.27, a current ratio of 0.94 and a debt-to-equity ratio of 0.99. Target ( NYSE:TGT – Get Free Report ) last released its quarterly earnings results on Wednesday, November 20th. The retailer reported $1.85 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.45). Target had a net margin of 4.06% and a return on equity of 31.11%. The firm had revenue of $25.23 billion for the quarter, compared to the consensus estimate of $25.87 billion. During the same period in the previous year, the business earned $2.10 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Sell-side analysts expect that Target will post 9.58 EPS for the current fiscal year. Target Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Wednesday, November 20th will be issued a dividend of $1.12 per share. The ex-dividend date of this dividend is Wednesday, November 20th. This represents a $4.48 dividend on an annualized basis and a dividend yield of 3.58%. Target’s dividend payout ratio is presently 47.51%. Target Company Profile ( Get Free Report Target Corporation operates as a general merchandise retailer in the United States. The company offers apparel for women, men, boys, girls, toddlers, and infants and newborns, as well as jewelry, accessories, and shoes; and beauty and personal care, baby gear, cleaning, paper products, and pet supplies. See Also Five stocks we like better than Target Buy P&G Now, Before It Sets A New All-Time High Vertiv’s Cool Tech Makes Its Stock Red-Hot The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number MarketBeat Week in Review – 11/18 – 11/22 What is a Special Dividend? 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Target Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Target and related companies with MarketBeat.com's FREE daily email newsletter .
Lowtemp Industries Releases Groundbreaking New Concentrate Dispenser That Increases Cannabis Extracts Packaging Efficiency by Over 800%Jonah Goldberg Among elites across the ideological spectrum, there's one point of unifying agreement: Americans are bitterly divided. What if that's wrong? What if elites are the ones who are bitterly divided while most Americans are fairly unified? History rarely lines up perfectly with the calendar (the "sixties" didn't really start until the decade was almost over). But politically, the 21st century neatly began in 2000, when the election ended in a tie and the color coding of electoral maps became enshrined as a kind of permanent tribal color war of "red vs. blue." Elite understanding of politics has been stuck in this framework ever since. Politicians and voters have leaned into this alleged political reality, making it seem all the more real in the process. I loathe the phrase "perception is reality," but in politics it has the reifying power of self-fulfilling prophecy. People are also reading... Recap: Here's how Joey Graziadei will win 'Dancing with the Stars' They fell in love with Beatrice. So they opened a store in downtown. At the courthouse, Nov. 23, 2024 Search warrants lead to arrest of man in narcotics investigation No change in bond amounts in child abuse death case Clabaugh family presents Outstanding Educator award Harmonizers to perform Courthouse lighting ceremony planned for Sunday Kidnapping in Nebraska prompted police chase that ended with 3 dead on I-29 in Missouri Inside Nebraska volleyball’s finishing kick for a Big Ten title: First up, Wisconsin Zitel bound over to district court in death of child Just Askin': Dana Holgorsen noncommittal on future, ranking a big week for Nebraska Athletics Streaming review: 'Landman' gives Billy Bob Thornton a real gusher of a series Amie Just: Bring out the tissues — and the brooms — for Nebraska volleyball's emotional win At the courthouse, Nov. 16, 2024 Like rival noble families in medieval Europe, elites have been vying for power and dominance on the arrogant assumption that their subjects share their concern for who rules rather than what the rulers can deliver. Gobble up these 14 political cartoons about Thanksgiving Political cartoonists from across country draw up something special for the holiday In 2018, the group More in Common published a massive report on the "hidden tribes" of American politics. The wealthiest and whitest groups were "devoted conservatives" (6%) and "progressive activists" (8%). These tribes dominate the media, the parties and higher education, and they dictate the competing narratives of red vs. blue, particularly on cable news and social media. Meanwhile, the overwhelming majority of Americans resided in, or were adjacent to, the "exhausted majority." These people, however, "have no narrative," as David Brooks wrote at the time. "They have no coherent philosophic worldview to organize their thinking and compel action." Lacking a narrative might seem like a very postmodern problem, but in a postmodern elite culture, postmodern problems are real problems. It's worth noting that red vs. blue America didn't emerge ex nihilo. The 1990s were a time when the economy and government seemed to be working, at home and abroad. As a result, elites leaned into the narcissism of small differences to gain political and cultural advantage. They remain obsessed with competing, often apocalyptic, narratives. That leaves out most Americans. The gladiatorial combatants of cable news, editorial pages and academia, and their superfan spectators, can afford these fights. Members of the exhausted majority are more interested in mere competence. I think that's the hidden unity elites are missing. This is why we keep throwing incumbent parties out of power: They get elected promising competence but get derailed -- or seduced -- by fan service to, or trolling of, the elites who dominate the national conversation. There's a difference between competence and expertise. One of the most profound political changes in recent years has been the separation of notions of credentialed expertise from real-world competence. This isn't a new theme in American life, but the pandemic and the lurch toward identity politics amplified distrust of experts in unprecedented ways. This is a particular problem for the left because it is far more invested in credentialism than the right. Indeed, some progressives are suddenly realizing they invested too much in the authority of experts and too little in the ability of experts to provide what people want from government, such as affordable housing, decent education and low crime. The New York Times' Ezra Klein says he's tired of defending the authority of government institutions. Rather, "I want them to work." One of the reasons progressives find Trump so offensive is his absolute inability to speak the language of expertise -- which is full of coded elite shibboleths. But Trump veritably shouts the language of competence. I don't mean he is actually competent at governing. But he is effectively blunt about calling leaders, experts and elites -- of both parties -- stupid, ineffective, weak and incompetent. He lost in 2020 because voters didn't believe he was actually good at governing. He won in 2024 because the exhausted majority concluded the Biden administration was bad at it. Nostalgia for the low-inflation pre-pandemic economy was enough to convince voters that Trumpian drama is the tolerable price to pay for a good economy. About 3 out of 4 Americans who experienced "severe hardship" because of inflation voted for Trump. The genius of Trump's most effective ad -- "Kamala is for they/them, President Trump is for you" -- was that it was simultaneously culture-war red meat and an argument that Harris was more concerned about boutique elite concerns than everyday ones. If Trump can actually deliver competent government, he could make the Republican Party the majority party for a generation. For myriad reasons, that's an if so big it's visible from space. But the opportunity is there -- and has been there all along. Goldberg is editor-in-chief of The Dispatch: thedispatch.com . Get opinion pieces, letters and editorials sent directly to your inbox weekly!
Jennison Associates LLC Purchases New Position in Powell Industries, Inc. (NASDAQ:POWL)